Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ORIC
Stock Latest News
Ratings
ORIC Pharma: Buy Rating on Rinzimetostat’s Promising Efficacy, Favorable Safety, and 2026 MEVPRO-1 Readout Catalyst
16d ago
ORIC
Premium
The Fly
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
16d ago
ORIC
Premium
Ratings
ORIC Pharmaceuticals: Buy Rating Backed by Advancing Oncology Pipeline, Phase 3 Prostate Cancer Trial and 2026 NSCLC Data Catalysts
25d ago
ORIC
Premium
The Fly
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
26d ago
ORIC
Premium
The Fly
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
26d ago
ORIC
Premium
The Fly
Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR
1M ago
ORIC
Premium
Market News
3 Best Stocks to Buy amid the Market Pullback, According to Top Analysts
2M ago
ENGN
ORIC
Premium
The Fly
Oric selloff brings attractive entry point, says H.C. Wainwright
2M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals should be bought on selloff, says Citi
2M ago
ORIC
Premium
The Fly
Midday Fly By: Nike falls after earnings, Conagra reports mixed results
2M ago
LW
RH
Premium
The Fly
Oric Pharmaceuticals price target lowered to $17 from $20 at Wedbush
2M ago
PFE
ORIC
Premium
The Fly
Oric’s rinzi efficacy ‘comparable’ to Pfizer’s mevro, says Cantor Fitzgerald
2M ago
PFE
ORIC
Premium
The Fly
Oric selloff on cancer data ‘appears exaggerated,’ says JonesResearch
2M ago
ORIC
Premium
The Fly
Video: Nike stumbles as timeline for recovery pushed out
2M ago
RH
TH
Premium
Company Announcements
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3
2M ago
8K
ORIC
Premium
The Fly
Closing Bell Movers: Nike slides 9% after Q3 results, soft outlook
2M ago
RH
NKE
Premium
The Fly
Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update
2M ago
ORIC
Premium
The Fly
Oric selloff brings favorable entry point, says H.C. Wainwright
3M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals reports Q4 revenue C$17.39M vs. C$18.04M last year
3M ago
ORIC
Premium
Ratings
Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat
3M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals selloff a buying opportunity, says JPMorgan
3M ago
ORIC
Premium
The Fly
Cantor says Oric move down on tazemetostat withdrawal an ‘over-reaction’
3M ago
ORIC
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
